Postmarketing Surveillance Study With MOBEC®

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate

• the indication for MOBEC in a dose of 15 mg per day

• the treatments patients were receiving before switching to 15 mg MOBEC

• how treatment with 15 mg is assessed compared with previous treatment

• how effective and safe treatment with 15 mg MOBEC is considered

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Meloxicam

Criteria

Inclusion Criteria:

• An indication for a treatment with 15 mg MOBEC of at least four weeks

• the symptomatic short-term treatment of osteoarthritis

• the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg)

• the symptomatic treatment of ankylosing spondylitis

Exclusion Criteria:

• Treatment with MOBEC prior to the start of the study

• Patients with any of the general or specific contraindications of MOBEC